Evidence map›Paper›PMID 30348938›Full record

ArticleMedical science monitor basic research2018

Association of Serum T cell Immunoglobulin Domain and Mucin-3 and Interleukin-17 with Systemic Lupus Erythematosus.

Lairun Jin, Ran Bai, Jun Zhou, Wei Shi, Liang Xu, Jun Sheng, Hui Peng, Yuelong Jin, Hui Yuan

Open access · greenAbstract read
In one paragraph

Article in Medical science monitor basic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lairun JinSchool of Public Health, Wannan Medical College, Wuhu, Anhui, China (mainland).
Ran BaiSchool of Public Health, Wannan Medical College, Wuhu, Anhui, China (mainland).
Jun ZhouSchool of Public Health, Wannan Medical College, Wuhu, Anhui, China (mainland).
Wei ShiSchool of Public Health, Wannan Medical College, Wuhu, Anhui, China (mainland).
Liang XuDepartment of Rheumatology, Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China (mainland).
Jun ShengDepartment of Rheumatology, Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China (mainland).
Hui PengAdministration Office of Hospital Admission and Discharge, Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China (mainland).
Yuelong JinSchool of Public Health, Wannan Medical College, Wuhu, Anhui, China (mainland).
Hui YuanSchool of Public Health, Wannan Medical College, Wuhu, Anhui, China (mainland).
Wannan Medical College · CNFirst Affiliated Hospital of Wannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Previous studies have shown that T cell immunoglobulin domain and mucin-3 (Tim-3) and interleukin-17 (IL-17) are implicated in the development of several autoimmune diseases. However, it is unclear whether these proteins contribute to the pathogenesis of systemic lupus erythematosus (SLE). The purpose of this study was to evaluate SLE patient serum Tim-3 and IL-17 levels, and to assess correlations between these proteins and major clinical parameters of SLE. MATERIAL AND METHODS Overall, 55 SLE patients and 55 healthy controls were recruited in a case-control study. Serum Tim-3 and IL-17 levels were quantified using an enzyme-linked immunosorbent assay (ELISA) kit. RESULTS Serum Tim-3 and IL-17 levels in SLE patients were significantly elevated relative to healthy controls (all P<0.05). Serum Tim-3 levels were significantly lower in SLE patients with nephritis than in those SLE without nephritis (P<0.05), while no statistically significant correlation between serum IL-17 and nephritis was detected (P>0.05). Serum Tim-3 with IL-17 levels were positively correlated in SLE patients (rs=0.817, P<0.01); however, no statistically significant correlation was found between serum Tim-3 or IL-17 levels and systemic lupus erythematosus disease activity index (SLEDAI) scores in those with SLE (all P>0.05). In addition, serum Tim-3 was associated with central lesions in SLE patients, while there were no significant correlations between serum Tim-3 or IL-17 levels and other SLE clinical parameters. CONCLUSIONS Increased serum Tim-3 and IL-17 levels and their clinical associations in SLE patients suggest their possible role in this disease.

Indexed as

AdultCase-Control StudiesFemaleHepatitis A Virus Cellular Receptor 2HumansImmunoglobulin DomainsInterleukin-17Lupus Erythematosus, SystemicMaleMiddle AgedMucin-3Severity of Illness IndexT-LymphocytesHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2IL17A protein, humanInterleukin-17Mucin-3

Identifiers

PMID30348938
PMCPMC6213872
OpenAlexW2896869484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.